SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01027663

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Impact of Host Iron Status and Iron Supplement Use on Growth and Viability of the Erythrocytic Stage of Plasmodium Falciparum

The purpose of this study is to perform laboratory based studies to determine if the growth and development of the malaria parasite is effected by iron status of its host (the person infected with the malaria parasite). Iron deficiency affects over 500 million people including many pregnant women and children from areas of the world that are plagued by malaria. Some population based studies have suggested that iron deficiency protects people from getting malaria and this has raised questions about the wisdom of public health policies that provide universal iron supplementation in countries where malaria is common. We will use red blood cells and sera from patients with iron deficiency anemia, hereditary hemochromatosis and normal individuals who are taking iron supplements to look at this question in a very systematic way. This study should provide information for or against a possible mechanism by which iron deficiency may affect the malaria parasite. The results will contribute to efforts to develop evidence-based public health policies on iron supplementation policies in malaria-endemic areas. There are three different types of individuals involved in this study (1) people with iron deficiency anemia who will be taking iron supplementation (2) people without iron deficiency anemia who will be taking iron supplementation and (3) people with a condition called hereditary hemochromatosis who have an excess of iron in their bodies.

NCT01027663 Iron Deficiency Anemia Malaria
MeSH: Malaria Anemia, Iron-Deficiency
HPO: Iron deficiency anemia

1 Interventions

Name: Iron Supplement

Description: Iron supplementation (325 mg of ferrous sulfate) once daily for the 2 month duration of the study.

Type: Dietary Supplement

Iron Supplements



Purpose: Basic Science

Allocation: Non-Randomized

Parallel Assignment


There are 2 SNPs

SNPs


1 C282Y

From the genotype standpoint, only patients homozygous for the C282Y and H63D mutations and those that are compound heterozygotes for C282Y/H63D will be enrolled. --- C282Y ---


2 H63D

From the genotype standpoint, only patients homozygous for the C282Y and H63D mutations and those that are compound heterozygotes for C282Y/H63D will be enrolled. --- C282Y --- --- H63D ---

From the genotype standpoint, only patients homozygous for the C282Y and H63D mutations and those that are compound heterozygotes for C282Y/H63D will be enrolled. --- C282Y --- --- H63D --- --- H63D ---



HPO Nodes


HPO:
Iron deficiency anemia
Genes 16
ABCD3 ATRX FAS HBB APC FASLG CLCNKB CD55 STK11 CASP10 DAXX ALAS2 CLPX WAS FOXP3 SLC12A3